Company intelligence / Profile preview
Adlai Nortye
North Brunswick, New Jersey, USAadlainortye.com ↗
- Ownership
- Public · ANL
- Development stage
- Other
01
Overview
Adlai Nortye’s lead candidate buparlisib (AN2025), a pan-class I PI3K inhibitor, is in a registrational Phase III trial for HNSCC post anti-PD(L)1 failure. Early data from their oral PD-L1 inhibitor AN4005 show encouraging safety and efficacy including one complete response in Phase I. Two additional candidates—AN8025 (a multifunctional fusion protein modulator of T cells/APCs) and AN9025 (oral pan-RAS(ON) inhibitor)—are expected to enter clinical trials by mid/late 2025[2][4][5]. The company has received Fast Track designation from the FDA for buparlisib.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesFusion proteins (multifunctional/trifunctional)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Novartis Pharma AG — global license agreement for buparlisib/BKM120 except certain rights retained by Novartis[6]Nucleai — collaboration on AI-powered biomarker discovery using digital pathology for patient stratification with buparlisib trials[4]
04
Financials
- Market cap
- $513.8M
- Total revenue
- $5M
- Enterprise value
- $308.6M
Beyond the preview
Go deeper on Adlai Nortye.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adlai Nortye.